VOYAGER-PAD helps to underscore that peripheral artery disease is a different disease state than coronary disease and different than stroke. Although they're all unified by an underlying biology of atherosclerosis, the character and the nature of that disease is different, said Marc P. Bonaca, MD, MPH, cardiologist and vascular medicine specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health.
VOYAGER-PAD helps to underscore that peripheral artery disease is a different disease state than coronary disease and different than stroke. Although they're all unified by an underlying biology of atherosclerosis, the character and the nature of that disease is different, said Marc P. Bonaca, MD, MPH, cardiologist and vascular medicine specialist who is affiliated with the University of Colorado School of Medicine and serves as the Executive Director of CPC Clinical Research and CPC Community Health.
Transcript
What findings from VOYAGER-PAD will be of greatest interest to cardiologists?
That's a great question. [With] VOYAGER-PAD really there are a couple of different audiences. There's the vascular practitioner—many of the vascular surgeons or interventional radiologists, they know that limb outcomes are really critical and the patency of the interventions are important. I think for them, the results will be compelling. I think for cardiologists there has been often the notion that patients with PAD [peripheral artery disease] are just sort of another high-risk subgroup of cardiology trials–so high risk of heart attack and stroke.
That is true, but I don't think in the cardiology community that things like acute limb ischemia are actually more frequent than heart attack and stroke, and just as bad or worse. So I think, for the broader community, understanding the epidemiology of this disease state—how high the risk is, the role that limb events play, the role of prothrombin thrombosis, and that will be really critical. Then I think the broad benefits of rivaroxabon for those events that are happening in this population will be a key observation.
VOYAGER helps to underscore that PAD is a different disease state than coronary disease and different than stroke. Although they're all unified by an underlying biology of atherosclerosis, the character and the nature of that disease is different. The population in VOYAGER is very sick—a lot of comorbidity. You can tell just from the mortality rate, how sick the population is, yet only 11% ever had a plaque rupture event or myocardial infarction.
So it's just very different than an ACS [acute coronary syndrome] population. I hope that VOYAGER is the first of many trials that will be dedicated to examining this distinct population and the relevant outcomes in this population to understand how to improve outcomes. There have been many cardiology trials and very few PAD trials, and even fewer that have been positive. So, I think we need more work in this field, and I hope VOYAGER leads the way for that.
If more patients with PAD could be successfully treated with medication, what would this mean for population health? What would it mean for savings in Medicare and health systems?
I think some of the key features for peripheral artery disease and for the clinicians that take care of it is that these patients, they're never seen once right, especially after intervention. These patients come back frequently with complications of the intervention, but also complications of their disease, including cardiovascular disease—it’s a very high risk group and that’s very costly. If you look at what's likely to happen to these patients, about 1 in 4 over the next 2 or 3 years needs another procedure on their limbs.
So medical therapies that reduce the risks not only of heart attack and stroke, but also of limb outcomes and the need for recurrent revascularisation have a big impact on cost. So, if you think of the cost benefits of preventing heart attack and stroke, this is about 2-fold that and an important driver of utilization in this population. So, I think any medical therapy that can reduce the need for recurrent limb interventions as well as other heart outcomes will save money.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More